Agilent Technologies Inc. announced today that it will present a range of next?generation automated workflow innovations at the SLAS2026 International Conference & Exhibition, taking place February 7?

Analytik Jena will present a range of automation solutions for laboratory workflows at the SLAS 2026 International Conference ...

Analytik Jena will be presenting new automation solutions for laboratory workflows at the SLAS 2026 International Conference & Exhibition (February 7–11). A particular highlight is the launch of the ...

As a veteran who was wounded during a mortar attack in Iraq, I’m all too familiar with the fact that our enemies can hit us with little warning. I’ve seen firsthand what happens when we underestimate ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co ...

Your report “Boston’s Biotech Engine Is Sputtering” (U.S. News, Dec. 30) rightly notes that highly trained Ph.D.s are struggling to find work as Boston’s biotech sector contracts. But the problem ...

Pharmas will need to provide their latest stance on the Most Favored Nation drug pricing plans, while biotech finally gets a break after a few tough years. Heading into the J.P. Morgan Healthcare ...

Jan 8 (Reuters) - Merck (MRK.N), opens new tab is in talks to buy cancer drug developer Revolution Medicines (RVMD.O), opens new tab in a $28 billion to $32 billion deal, the Financial Times reported ...

After holding its breath for several rough years, Greater Boston’s life sciences sector is cautiously coming up for air. It was a year of devastating uncertainty for the sector and its roughly 75,000 ...

Radiopharmaceutical drug developer Aktis Oncology on Thursday said it raised $318 million from an initial public offering, the first for a biotechnology company in 2026. The company, which is based in ...

Some of the best-selling drugs in the world are facing a loss of exclusivity in key jurisdictions in the upcoming years in what the sector calls "the patent cliff." The need for pharma to top up their ...